{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:11:28Z","timestamp":1788901888023,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cca.2026.121187","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:22:20Z","timestamp":1781713340000},"page":"121187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectives"],"prefix":"10.1016","volume":"592","author":[{"given":"Asif Ahmad","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tahir","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Agnihotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Seng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanalekshmi Unnikrishnan","family":"Meenakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cca.2026.121187_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/cells15040338","article-title":"Inside the battle against acute myeloid leukemia: biology, breakthroughs, and hope","volume":"15","author":"Bao","year":"2026","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.cca.2026.121187_bb0010","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/10428194.2024.2360536","article-title":"A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden","volume":"65","author":"Anderson","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cca.2026.121187_bb0015","article-title":"Global, regional, and national burden of leukemia, 1990\u20132021: a systematic analysis of the global burden of disease in 2021","volume":"12","author":"Chen","year":"2025","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.cca.2026.121187_bb0020","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.cca.2026.121187_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162915","article-title":"Comparative analysis of AML classification systems: evaluating the WHO, ICC, and ELN frameworks and their distinctions","volume":"16","author":"Salman","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.cca.2026.121187_bb0030","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-024-02378-5","article-title":"Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)","volume":"38","author":"Rodr\u00edguez-Arbol\u00ed","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121187_bb0035","series-title":"Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)","author":"Gunaratne","year":"2026"},{"issue":"2","key":"10.1016\/j.cca.2026.121187_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41409-024-02481-2","article-title":"Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice","volume":"60","author":"Shaffer","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.cca.2026.121187_bb0045","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.cca.2026.121187_bb0050","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1042\/BCJ20210425","article-title":"Phosphatidylserine binding directly regulates TIM-3 function","volume":"478","author":"Smith","year":"2021","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.cca.2026.121187_bb0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.61186\/ibj.3874","article-title":"Engineering a CEACAM1 variant with increased binding affinity to TIM-3 receptor","volume":"27","author":"Hajihassan","year":"2023","journal-title":"Iran. Biomed. J."},{"issue":"2","key":"10.1016\/j.cca.2026.121187_bb0060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1385690","article-title":"Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy","volume":"7","author":"Sabatos-Peyton","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cca.2026.121187_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbior.2018.09.003","article-title":"Galectins as regulators of cell survival in the leukemia niche","volume":"71","author":"Ruvolo","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.cca.2026.121187_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01594","article-title":"The Tim-3-Galectin-9 pathway and its regulatory mechanisms in human breast cancer","volume":"10","author":"Yasinska","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121187_bb0075","article-title":"Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target","volume":"11","author":"Zhang","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0080","article-title":"Single-cell mass cytometry characterizes phenotypic and functional heterogeneity in acute myeloid leukemia at diagnosis, in remission and relapse","volume":"132","author":"Han","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"36","key":"10.1016\/j.cca.2026.121187_bb0090","doi-asserted-by":"crossref","first-page":"57811","DOI":"10.18632\/oncotarget.11063","article-title":"Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1","volume":"7","author":"Darwish","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cca.2026.121187_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071320","article-title":"Characterization of CD34(+) cells from patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using a t-distributed stochastic neighbor embedding (t-SNE) protocol","volume":"16","author":"Nollmann","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.121187_bb0100","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-5615","article-title":"Searching for a myelodysplastic syndrome stem cells (MDS-SCs) signature by flow cytometry: toward a new prognostic tool?","volume":"146","author":"Pacelli","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121187_bb0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-3483","article-title":"Real-life CD34+CD38\u2212 leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: a study of prospective observational ALFA-PPP acute leukemia French association","volume":"146","author":"Plesa","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2026.121187_bb0110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0115","article-title":"Identification of TIM-3\/Gal-9 autocrine loop as a novel Wnt-ligands-independent machinery for the constitutive activation of canonical Wnt pathway in AML-LSCs","volume":"132","author":"Sakoda","year":"2018","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.cca.2026.121187_bb0120","doi-asserted-by":"crossref","first-page":"33823","DOI":"10.18632\/oncotarget.5257","article-title":"Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells","volume":"6","author":"Gon\u00e7alves Silva","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.cca.2026.121187_bb0125","first-page":"602","article-title":"Oridonin could inhibit inflammation and T-cell immunoglobulin and mucin-3\/Galectin-9 (TIM-3\/Gal-9) autocrine loop in the acute myeloid leukemia cell line (U937) as compared to doxorubicin","volume":"19","author":"Nasri","year":"2020","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-11898-3","article-title":"TIM-3\/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1","volume":"24","author":"Shapourian","year":"2024","journal-title":"BMC Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.cca.2026.121187_bb0135","article-title":"Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity","volume":"8","author":"Sabatos-Peyton","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428194.2021.1966785","article-title":"Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8,21) acute myeloid leukemia","volume":"63","author":"Wang","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cca.2026.121187_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.879471","article-title":"TIM-3 expression level on AML blasts correlates with presence of core binding factor translocations rather than clinical outcomes","volume":"12","author":"Hong","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0155","article-title":"Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia","volume":"13","author":"Huang","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.cca.2026.121187_bb0160","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cas.16431","article-title":"TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation","volume":"116","author":"Sakoda","year":"2025","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.cca.2026.121187_bb0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.55133\/eji.320306","article-title":"T-cell immunoglobulin mucin-3 expression levels in pediatric acute myeloid leukemia","volume":"32","author":"Sultan","year":"2025","journal-title":"Egypt. J. Immunol."},{"issue":"2","key":"10.1016\/j.cca.2026.121187_bb0170","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cyto.b.22049","article-title":"Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia","volume":"102","author":"Huang","year":"2022","journal-title":"Cytometry B Clin. Cytom."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2026.121187_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML","volume":"8","author":"Tan","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.cca.2026.121187_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.763773","article-title":"Bone marrow-resident V\u03b41 T cells co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma","volume":"8","author":"Brauneck","year":"2021","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2278229","article-title":"Higher PD-1\/Tim-3 expression on IFN-\u03b3+ T cells is associated with poor prognosis in patients with acute myeloid leukemia","volume":"24","author":"Huang","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cca.2026.121187_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1386517","article-title":"Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1(+)TIM3(+) exhausted CD8(+) T cells","volume":"15","author":"Corradi","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cca.2026.121187_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12122717","article-title":"The functional role and prognostic significance of TIM-3 expression on NK cells in the diagnostic bone marrows in acute myeloid leukemia","volume":"12","author":"Sun","year":"2024","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.cca.2026.121187_bb0205","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04169-y","article-title":"Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival","volume":"74","author":"Valhondo","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"16","key":"10.1016\/j.cca.2026.121187_bb0210","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae191","article-title":"Features and prognostic significance of soluble TIM-3 and its ligands Gal-9 and CEACAM1 levels in the diagnostic bone marrow of adult acute myeloid leukemia patients","volume":"117","author":"Shi","year":"2025","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.cca.2026.121187_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0225","article-title":"Flow MRD monitoring combining LAIP\/DfN and CD34+CD38\u2212 LSCs is a strong predictor of outcome in adult AML independently of the ELN-2022 risk: first results from the multicentric Acute Leukemia French Intergroup MRD Flow Network","volume":"144","author":"Plesa","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0230","article-title":"Leukemic stem cell measurable residual disease (LSC MRD) status is a better predictor of relapse than multiparametric flowcytometric analysis in acute myeloid leukemia patients","volume":"144","author":"Mawalankar","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121187_bb0235","doi-asserted-by":"crossref","first-page":"1724473","DOI":"10.3389\/fphar.2025.1724473","article-title":"Flow cytometric detection of leukemic stem cells in acute myeloid leukemia: current status and future directions","volume":"16","author":"Youssef","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.cca.2026.121187_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052847","article-title":"Phenotypic analysis of hematopoietic stem and progenitor cell populations in acute myeloid leukemia based on spectral flow cytometry, a 20-color panel, and unsupervised learning algorithms","volume":"25","author":"Matthes","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cca.2026.121187_bb0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cyto.a.24958","article-title":"Development of a 29-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease and leukemic stem cells in acute myeloid leukemia","volume":"107","author":"Zhang","year":"2025","journal-title":"Cytometry A"},{"issue":"8","key":"10.1016\/j.cca.2026.121187_bb0250","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.7150\/ijms.108527","article-title":"Gene signature-based prognostic model for acute myeloid leukemia: the role of BATF, EGR1, PD-1, PD-L1, and TIM-3","volume":"22","author":"Zhang","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.cca.2026.121187_bb0255","article-title":"Construction of a novel inflammatory-related prognostic signature of acute myelocytic leukemia based on conjoint analysis of single-cell and bulk RNA sequencing","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cca.2026.121187_bb0260","article-title":"Robust preanalytical performance of soluble PD-1, PD-L1 and PD-L2 assessed by sensitive ELISAs in blood","volume":"10","author":"Krueger","year":"2022","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.cca.2026.121187_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082011","article-title":"Quality assessment of a large multi-center flow cytometric dataset of acute myeloid leukemia patients: a EuroFlow study","volume":"14","author":"Bras","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0270","article-title":"Stability assessment of fresh or cryopreserved whole blood and bone marrow samples from AML and B-ALL patients to monitor CD123 receptor and immune cells subsets","volume":"142","author":"Courta","year":"2023","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0275","article-title":"Multicentric standardization of minimal\/measurable residual disease in acute myeloid leukemia using multiparametric flow cytometry: a Brazilian Society of Bone Marrow Transplantation (SBTMO) project","volume":"144","author":"Furtado","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0280","article-title":"Clinical feasibility of peripheral blood-based MRD monitoring using the miselect R AML MRD assay in acute myeloid leukemia","volume":"146","author":"Tsai","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121187_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1799028","article-title":"A standardized single-tube 17-color spectral flow cytometry workflow for integrated immunophenotyping of human PBMCs and mixed co-culture systems","volume":"17","author":"Kiel","year":"2026","journal-title":"Front. Immunol."},{"issue":"60","key":"10.1016\/j.cca.2026.121187_bb0290","doi-asserted-by":"crossref","first-page":"102088","DOI":"10.18632\/oncotarget.22141","article-title":"High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0295","article-title":"Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0300","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0305","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat. Can."},{"issue":"8","key":"10.1016\/j.cca.2026.121187_bb0310","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.clml.2021.03.009","article-title":"Leukemic stem cell (CD34(+)\/CD38(\u2212)\/TIM3(+)) frequency in patients with acute myeloid leukemia: clinical implications","volume":"21","author":"Mohamed","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0315","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1889822","article-title":"TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients","volume":"10","author":"Rakova","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0320","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cca.2026.121187_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.579351","article-title":"TIM-3 as a prognostic marker and a potential immunotherapy target in human malignant tumors: a meta-analysis and bioinformatics validation","volume":"11","author":"Zang","year":"2021","journal-title":"Front. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0330","article-title":"TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) detected after allogeneic stem cell transplantation (AlloSCT): preliminary findings from the phase Ib\/II STIMULUS-AML2 study","volume":"142","author":"Zeiser","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2026.121187_bb0335","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/ajh.25918","article-title":"Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling","volume":"95","author":"Daga","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0340","article-title":"Single-cell multi-omic analysis of AML MRD reveals differences in clonal architecture between relapse and non-relapse cases","volume":"144","author":"Sciambi","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0345","volume":"146","author":"Alasbali","year":"2025","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0350","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1182\/blood-2025-7033","article-title":"IL1RAP, but not CD366 (TIM3), may aid the detection of abnormal myeloblasts in myeloid neoplasia by flow cytometry","volume":"146","author":"Ewing","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cca.2026.121187_bb0355","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cca.2026.121187_bb0360","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-021-01126-3","article-title":"Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia","volume":"35","author":"Paiva","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cca.2026.121187_bb0365","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cca.2026.121187_bb0370","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.121187_bb0375","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2021.12587","article-title":"Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: significance and impact on outcome","volume":"21","author":"Kamal","year":"2021","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0380","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/16078454.2020.1738097","article-title":"Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients","volume":"25","author":"Yegin","year":"2020","journal-title":"Hematology"},{"issue":"14","key":"10.1016\/j.cca.2026.121187_bb0385","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.7150\/jca.53686","article-title":"Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Cancer"},{"issue":"Spec Edition","key":"10.1016\/j.cca.2026.121187_bb0390","first-page":"S1","article-title":"Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy","volume":"5","author":"Kikushige","year":"2022","journal-title":"Blood Cell. Ther."},{"key":"10.1016\/j.cca.2026.121187_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267578","article-title":"TIM-3\/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines","volume":"14","author":"Rezaei","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0400","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-025-10396-4","article-title":"Effect of FLT3 ligand on the gene expression of TIM-3, HIF1-\u03b1, and TNF-\u03b1 in an acute myeloid leukemia cell line","volume":"52","author":"Heidari","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0405","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-137307","article-title":"Sabatolimab (MBG453) dose selection and dose-response analysis in myelodysplastic syndrome (MDS)\/acute myeloid leukemia (AML): population pharmacokinetics (PK) modeling and evaluation of clinical efficacy\/safety by dose","volume":"136","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0410","article-title":"Single-cell characterization of the immune and leukemic cells following anti-TIM3 and hypomethylating agent combination therapy in patients with AML or MDS","volume":"138","author":"Huuhtanen","year":"2021","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0415","article-title":"Safety and activity of the TIM3 inhibitor sabatolimab in patients with lower-risk myelodysplastic syndromes","volume":"144","author":"Brunner","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cca.2026.121187_bb0420","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2025029727","article-title":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials","volume":"147","author":"Stahl","year":"2026","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cca.2026.121187_bb0425","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) plus azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0430","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-023-00421-2","article-title":"Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting","volume":"12","author":"Tan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0435","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-026-02133-3","article-title":"TIM-3 in AML: pathogenic roles and therapeutic targetability","volume":"26","author":"Zhong","year":"2026","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0440","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol. Biomed."},{"issue":"8","key":"10.1016\/j.cca.2026.121187_bb0445","article-title":"Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8(+) T-cell exhaustion and anti-PD-1 resistance","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"11","key":"10.1016\/j.cca.2026.121187_bb0450","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/psp4.12962","article-title":"Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome\/acute myeloid leukemia and solid tumors","volume":"12","author":"Xu","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.cca.2026.121187_bb0455","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","article-title":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","volume":"36","author":"R\u00f6hnert","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0460","volume":"146","author":"B\u00f6ttcher","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121187_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00700-x","article-title":"Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models","volume":"4","author":"Mocking","year":"2024","journal-title":"Commun. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121187_bb0470","article-title":"Machine learning enhancement of flow cytometry data accelerates the identification of minimal residual acute myeloid leukemia","volume":"142","author":"Seheult","year":"2023","journal-title":"Blood"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:49:15Z","timestamp":1788900555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126003694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":94,"alternative-id":["S0009898126003694"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121187","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121187"}}